DB:107

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. More Details


Snowflake Analysis

Slightly overvalued with imperfect balance sheet.

Share Price & News

How has Bioasis Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 107's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-6.2%

107

-3.2%

DE Biotechs

-7.3%

DE Market


1 Year Return

71.3%

107

-8.0%

DE Biotechs

-7.7%

DE Market

Return vs Industry: 107 exceeded the German Biotechs industry which returned -6.3% over the past year.

Return vs Market: 107 exceeded the German Market which returned -6.6% over the past year.


Shareholder returns

107IndustryMarket
7 Day-6.2%-3.2%-7.3%
30 Day-13.6%-15.4%-7.7%
90 Day18.0%-14.5%-4.5%
1 Year71.3%71.3%-7.9%-8.0%-4.8%-7.7%
3 Year-65.7%-65.7%-5.3%-6.2%-9.2%-17.2%
5 Yearn/a36.1%34.5%11.4%-4.5%

Price Volatility Vs. Market

How volatile is Bioasis Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Bioasis Technologies undervalued compared to its fair value and its price relative to the market?

32.6%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 107 (€0.2) is trading below our estimate of fair value (€0.29)

Significantly Below Fair Value: 107 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 107 is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: 107 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 107's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 107 has negative assets, so we can't compare its PB Ratio to the DE Biotechs industry average.


Next Steps

Future Growth

How is Bioasis Technologies forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-32.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 107 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 107 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 107 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 107's revenue is expected to decline over the next 3 years (-22.1% per year).

High Growth Revenue: 107's revenue is forecast to decline over the next 3 years (-22.1% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 107's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Bioasis Technologies performed over the past 5 years?

-4.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 107 is currently unprofitable.

Growing Profit Margin: 107 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 107 is unprofitable, and losses have increased over the past 5 years at a rate of 4.4% per year.

Accelerating Growth: Unable to compare 107's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 107 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (15.2%).


Return on Equity

High ROE: 107's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Bioasis Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: 107 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 107 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 107 has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: 107's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 107 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 107 is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 6.5% per year.


Next Steps

Dividend

What is Bioasis Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 107's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 107's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 107's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 107's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 107's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Deborah Rathjen (62 yo)

1.58yrs

Tenure

CA$105,352

Compensation

Dr. Deborah Ann Rathjen, B.Sc. (Hons.), Ph.D., M.A.I.C.D., FTSE, Q.C. has been the President and Chief Executive Officer of Bioasis Technologies Inc. since March 11, 2019. Dr. Rathjen served as the Chief E ...


Leadership Team

NamePositionTenureCompensationOwnership
Deborah Rathjen
Executive Chairman1.58yrsCA$105.35k0.26%
CA$ 40.3k
Christine Antalik
Chief Financial Officer1.75yrsCA$304.70kno data
Graeme Dick
Director of Investor Relationsno datano datano data
Kim Elton
Director of Marketingno datano datano data
Doug Williams
Executive VP & Chief Business Officer3.17yrsno datano data
Mei Tian
VP & Head of External Researchno datano datano data
May Orfali
Consultant Chief Medical Officer0.58yrno datano data

1.7yrs

Average Tenure

Experienced Management: 107's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Deborah Rathjen
Executive Chairman1.58yrsCA$105.35k0.26%
CA$ 40.3k
David Wurzer
Independent Lead Director1.83yrsCA$152.42k0.079%
CA$ 12.1k
Jeffrey Cummings
Member of Scientific Advisory Board3.08yrsno datano data
John Wikswo
Member of Scientific Advisory Board3.08yrsno datano data
John Krystal
Chairman of Scientific Advisory Board3.08yrsno datano data
Mario Saltarelli
Independent Non-Executive Director1.42yrsno datano data
Hope Rugo
Member of Medical Oncology Advisory Board0.83yrno datano data
Jack Hoppin
Member of Scientific Advisory Board2.33yrsno datano data
John de Groot
Member of Medical Oncology Advisory Board0.83yrno datano data
Sue O'Connor
Member of Scientific Advisory board2.33yrsno datano data
John Curran
Independent Director2.25yrsCA$152.42k0.079%
CA$ 12.1k
Javier Cortés
Member of Medical Oncology Advisory Board0.83yrno datano data

2.3yrs

Average Tenure

62yo

Average Age

Experienced Board: 107's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.6%.


Top Shareholders

Company Information

Bioasis Technologies Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bioasis Technologies Inc.
  • Ticker: 107
  • Exchange: DB
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$23.787m
  • Listing Market Cap: CA$15.340m
  • Shares outstanding: 67.96m
  • Website: https://www.bioasis.us

Location

  • Bioasis Technologies Inc.
  • 14 Water Street
  • Guilford
  • Connecticut
  • 6437
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BTITSXV (TSX Venture Exchange)YesCommon SharesCACADMar 2008
BIOA.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 2008
107DB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2008

Biography

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is d ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/30 22:08
End of Day Share Price2020/10/29 00:00
Earnings2020/08/31
Annual Earnings2020/02/29


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.